Item 7.01 Regulation FD Disclosure.
On June 10, 2021, Equillium, Inc. (the “Company”) issued a press release
announcing the Company’s presentation of data on target engagement and
modulation of CD6 on T Cells with Itolizumab at the International Society for
Advancement of Cytometry.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press release, dated June 10, 2021, issued by Equillium, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses